The comparative antitumor efficacy of a-PDL1-TGFβRII, a-PD-L1, nonspecific IgG-TGFβRII, and the combination of a-PD-L1 and IgG-TGFβRII against human cancers expressing both PD-L1 and TGFβ was evaluated in either A375 (Fig. 7a, b) or MDA-MB-231-Luc (Fig. 7c, d) bearing NSG mice reconstituted with human CD34+ hematopoietic stem cells (HSCs). Here, CD34 is linked to cancer.